内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

J Diabetes：西他列汀+二甲双胍 vs 磺酰脲类+二甲双胍，依从性更好

2016-11-18 MedSci MedSci原创

磺酰脲类二甲双胍西他列汀
关注

研究数据显示,服用西他列汀+二甲双胍的成年患者与服用磺酰脲类+二甲双胍的成年人相比，依从性和持久性均更好。 来自默克观测和真实世界证据研究中心的Swapnil N. Rajpathak博士和同事对14807名服用磺酰脲类+二甲双胍、14807名服用西他列汀+二甲双胍的2型糖尿病患只进行了研究。 服用西他列汀+二甲双胍的成年患者与服用磺酰脲类+二甲双胍的成年人相比，有更高的1年平均药物覆

研究数据显示,服用西他列汀+二甲双胍的成年患者与服用磺酰脲类+二甲双胍的成年人相比，依从性和持久性均更好。

来自默克观测和真实世界证据研究中心的Swapnil N. Rajpathak博士和同事对14807名服用磺酰脲类+二甲双胍、14807名服用西他列汀+二甲双胍的2型糖尿病患只进行了研究。

服用西他列汀+二甲双胍的成年患者与服用磺酰脲类+二甲双胍的成年人相比，有更高的1年平均药物覆盖天数比例。

服用西他列汀+二甲双胍的成年患者与服用磺酰脲类+二甲双胍的成年人相比，1年依从性更好（59.1% vs 55.9%;P < .001）；2年依从性同样更好（52.6% vs.49.9%; P = .007）；不过3年依从性就没有了组间差异。

与磺酰脲类+二甲双胍组比较，继续使用1、2和3年的西他列汀+二甲双胍组患者更多（P值均 < .05）。

西他列汀+二甲双胍组患者停药的可能性更小(P < .001)。

结果表明，服用西他列汀+二甲双胍的成年患者与服用磺酰脲类+二甲双胍的成年人相比，依从性和持久性均更好。

原始出处：

Bloomgarden ZT, et al. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.J Diabetes. 2016;doi:10.1111/1753-0407.12461.

Adherence high with sitagliptin plus metformin.Healio.November 17, 2016

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1642327, encodeId=10e5164232ebc, content=<a href='/topic/show?id=2e74e3891da' target=_blank style='color:#2F92EE;'>#磺酰脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73891, encryptionId=2e74e3891da, topicName=磺酰脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592c22907703, createdName=12498dabm84暂无昵称, createdTime=Sun Jan 15 10:49:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901506, encodeId=4ec4190150692, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 16 14:49:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759821, encodeId=6a361e59821ff, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Jul 27 09:49:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637551, encodeId=896e163e55120, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 19 12:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319264, encodeId=b3371319264c6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415991, encodeId=c62b141599136, content=<a href='/topic/show?id=f60890462d4' target=_blank style='color:#2F92EE;'>#西他列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90462, encryptionId=f60890462d4, topicName=西他列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f33125782, createdName=tcm100hq, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156862, encodeId=f08f156862af, content=值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMzGpMQ8w4I7FpiblCXNcmI6O7TDINutbaicEUpoYFR1rWqn3kTbulfMhT0iaPFurLz2ddEcWe3BiciaQ/0, createdBy=5f6e1724878, createdName=136****0753赵, createdTime=Sat Nov 19 11:55:18 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156784, encodeId=8fe3156e842d, content=这个研究背后问题很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 19 08:53:34 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156746, encodeId=4a48156e46e3, content=学习一下，赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sat Nov 19 07:18:28 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156706, encodeId=d78c156e06c4, content=学习了，多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Nov 19 00:04:25 CST 2016, time=2016-11-19, status=1, ipAttribution=)]
    2017-01-15 12498dabm84暂无昵称

    #磺酰脲类#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1642327, encodeId=10e5164232ebc, content=<a href='/topic/show?id=2e74e3891da' target=_blank style='color:#2F92EE;'>#磺酰脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73891, encryptionId=2e74e3891da, topicName=磺酰脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592c22907703, createdName=12498dabm84暂无昵称, createdTime=Sun Jan 15 10:49:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901506, encodeId=4ec4190150692, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 16 14:49:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759821, encodeId=6a361e59821ff, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Jul 27 09:49:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637551, encodeId=896e163e55120, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 19 12:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319264, encodeId=b3371319264c6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415991, encodeId=c62b141599136, content=<a href='/topic/show?id=f60890462d4' target=_blank style='color:#2F92EE;'>#西他列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90462, encryptionId=f60890462d4, topicName=西他列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f33125782, createdName=tcm100hq, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156862, encodeId=f08f156862af, content=值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMzGpMQ8w4I7FpiblCXNcmI6O7TDINutbaicEUpoYFR1rWqn3kTbulfMhT0iaPFurLz2ddEcWe3BiciaQ/0, createdBy=5f6e1724878, createdName=136****0753赵, createdTime=Sat Nov 19 11:55:18 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156784, encodeId=8fe3156e842d, content=这个研究背后问题很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 19 08:53:34 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156746, encodeId=4a48156e46e3, content=学习一下，赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sat Nov 19 07:18:28 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156706, encodeId=d78c156e06c4, content=学习了，多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Nov 19 00:04:25 CST 2016, time=2016-11-19, status=1, ipAttribution=)]
    2017-01-16 木头人513

    #Diabetes#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1642327, encodeId=10e5164232ebc, content=<a href='/topic/show?id=2e74e3891da' target=_blank style='color:#2F92EE;'>#磺酰脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73891, encryptionId=2e74e3891da, topicName=磺酰脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592c22907703, createdName=12498dabm84暂无昵称, createdTime=Sun Jan 15 10:49:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901506, encodeId=4ec4190150692, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 16 14:49:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759821, encodeId=6a361e59821ff, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Jul 27 09:49:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637551, encodeId=896e163e55120, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 19 12:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319264, encodeId=b3371319264c6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415991, encodeId=c62b141599136, content=<a href='/topic/show?id=f60890462d4' target=_blank style='color:#2F92EE;'>#西他列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90462, encryptionId=f60890462d4, topicName=西他列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f33125782, createdName=tcm100hq, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156862, encodeId=f08f156862af, content=值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMzGpMQ8w4I7FpiblCXNcmI6O7TDINutbaicEUpoYFR1rWqn3kTbulfMhT0iaPFurLz2ddEcWe3BiciaQ/0, createdBy=5f6e1724878, createdName=136****0753赵, createdTime=Sat Nov 19 11:55:18 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156784, encodeId=8fe3156e842d, content=这个研究背后问题很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 19 08:53:34 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156746, encodeId=4a48156e46e3, content=学习一下，赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sat Nov 19 07:18:28 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156706, encodeId=d78c156e06c4, content=学习了，多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Nov 19 00:04:25 CST 2016, time=2016-11-19, status=1, ipAttribution=)]
    2017-07-27 ms5439512287675881

    #BET#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1642327, encodeId=10e5164232ebc, content=<a href='/topic/show?id=2e74e3891da' target=_blank style='color:#2F92EE;'>#磺酰脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73891, encryptionId=2e74e3891da, topicName=磺酰脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592c22907703, createdName=12498dabm84暂无昵称, createdTime=Sun Jan 15 10:49:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901506, encodeId=4ec4190150692, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 16 14:49:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759821, encodeId=6a361e59821ff, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Jul 27 09:49:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637551, encodeId=896e163e55120, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 19 12:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319264, encodeId=b3371319264c6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415991, encodeId=c62b141599136, content=<a href='/topic/show?id=f60890462d4' target=_blank style='color:#2F92EE;'>#西他列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90462, encryptionId=f60890462d4, topicName=西他列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f33125782, createdName=tcm100hq, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156862, encodeId=f08f156862af, content=值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMzGpMQ8w4I7FpiblCXNcmI6O7TDINutbaicEUpoYFR1rWqn3kTbulfMhT0iaPFurLz2ddEcWe3BiciaQ/0, createdBy=5f6e1724878, createdName=136****0753赵, createdTime=Sat Nov 19 11:55:18 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156784, encodeId=8fe3156e842d, content=这个研究背后问题很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 19 08:53:34 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156746, encodeId=4a48156e46e3, content=学习一下，赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sat Nov 19 07:18:28 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156706, encodeId=d78c156e06c4, content=学习了，多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Nov 19 00:04:25 CST 2016, time=2016-11-19, status=1, ipAttribution=)]
    2017-08-19 ms9608593228839890

    #DIA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1642327, encodeId=10e5164232ebc, content=<a href='/topic/show?id=2e74e3891da' target=_blank style='color:#2F92EE;'>#磺酰脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73891, encryptionId=2e74e3891da, topicName=磺酰脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592c22907703, createdName=12498dabm84暂无昵称, createdTime=Sun Jan 15 10:49:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901506, encodeId=4ec4190150692, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 16 14:49:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759821, encodeId=6a361e59821ff, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Jul 27 09:49:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637551, encodeId=896e163e55120, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 19 12:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319264, encodeId=b3371319264c6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415991, encodeId=c62b141599136, content=<a href='/topic/show?id=f60890462d4' target=_blank style='color:#2F92EE;'>#西他列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90462, encryptionId=f60890462d4, topicName=西他列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f33125782, createdName=tcm100hq, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156862, encodeId=f08f156862af, content=值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMzGpMQ8w4I7FpiblCXNcmI6O7TDINutbaicEUpoYFR1rWqn3kTbulfMhT0iaPFurLz2ddEcWe3BiciaQ/0, createdBy=5f6e1724878, createdName=136****0753赵, createdTime=Sat Nov 19 11:55:18 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156784, encodeId=8fe3156e842d, content=这个研究背后问题很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 19 08:53:34 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156746, encodeId=4a48156e46e3, content=学习一下，赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sat Nov 19 07:18:28 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156706, encodeId=d78c156e06c4, content=学习了，多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Nov 19 00:04:25 CST 2016, time=2016-11-19, status=1, ipAttribution=)]
    2016-11-20 fyxzlh

    #依从性#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1642327, encodeId=10e5164232ebc, content=<a href='/topic/show?id=2e74e3891da' target=_blank style='color:#2F92EE;'>#磺酰脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73891, encryptionId=2e74e3891da, topicName=磺酰脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592c22907703, createdName=12498dabm84暂无昵称, createdTime=Sun Jan 15 10:49:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901506, encodeId=4ec4190150692, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 16 14:49:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759821, encodeId=6a361e59821ff, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Jul 27 09:49:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637551, encodeId=896e163e55120, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 19 12:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319264, encodeId=b3371319264c6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415991, encodeId=c62b141599136, content=<a href='/topic/show?id=f60890462d4' target=_blank style='color:#2F92EE;'>#西他列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90462, encryptionId=f60890462d4, topicName=西他列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f33125782, createdName=tcm100hq, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156862, encodeId=f08f156862af, content=值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMzGpMQ8w4I7FpiblCXNcmI6O7TDINutbaicEUpoYFR1rWqn3kTbulfMhT0iaPFurLz2ddEcWe3BiciaQ/0, createdBy=5f6e1724878, createdName=136****0753赵, createdTime=Sat Nov 19 11:55:18 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156784, encodeId=8fe3156e842d, content=这个研究背后问题很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 19 08:53:34 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156746, encodeId=4a48156e46e3, content=学习一下，赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sat Nov 19 07:18:28 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156706, encodeId=d78c156e06c4, content=学习了，多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Nov 19 00:04:25 CST 2016, time=2016-11-19, status=1, ipAttribution=)]
    2016-11-20 tcm100hq

    #西他列汀#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1642327, encodeId=10e5164232ebc, content=<a href='/topic/show?id=2e74e3891da' target=_blank style='color:#2F92EE;'>#磺酰脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73891, encryptionId=2e74e3891da, topicName=磺酰脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592c22907703, createdName=12498dabm84暂无昵称, createdTime=Sun Jan 15 10:49:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901506, encodeId=4ec4190150692, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 16 14:49:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759821, encodeId=6a361e59821ff, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Jul 27 09:49:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637551, encodeId=896e163e55120, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 19 12:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319264, encodeId=b3371319264c6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415991, encodeId=c62b141599136, content=<a href='/topic/show?id=f60890462d4' target=_blank style='color:#2F92EE;'>#西他列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90462, encryptionId=f60890462d4, topicName=西他列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f33125782, createdName=tcm100hq, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156862, encodeId=f08f156862af, content=值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMzGpMQ8w4I7FpiblCXNcmI6O7TDINutbaicEUpoYFR1rWqn3kTbulfMhT0iaPFurLz2ddEcWe3BiciaQ/0, createdBy=5f6e1724878, createdName=136****0753赵, createdTime=Sat Nov 19 11:55:18 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156784, encodeId=8fe3156e842d, content=这个研究背后问题很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 19 08:53:34 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156746, encodeId=4a48156e46e3, content=学习一下，赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sat Nov 19 07:18:28 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156706, encodeId=d78c156e06c4, content=学习了，多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Nov 19 00:04:25 CST 2016, time=2016-11-19, status=1, ipAttribution=)]
    2016-11-19 136****0753赵

    值得学习。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1642327, encodeId=10e5164232ebc, content=<a href='/topic/show?id=2e74e3891da' target=_blank style='color:#2F92EE;'>#磺酰脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73891, encryptionId=2e74e3891da, topicName=磺酰脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592c22907703, createdName=12498dabm84暂无昵称, createdTime=Sun Jan 15 10:49:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901506, encodeId=4ec4190150692, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 16 14:49:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759821, encodeId=6a361e59821ff, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Jul 27 09:49:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637551, encodeId=896e163e55120, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 19 12:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319264, encodeId=b3371319264c6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415991, encodeId=c62b141599136, content=<a href='/topic/show?id=f60890462d4' target=_blank style='color:#2F92EE;'>#西他列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90462, encryptionId=f60890462d4, topicName=西他列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f33125782, createdName=tcm100hq, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156862, encodeId=f08f156862af, content=值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMzGpMQ8w4I7FpiblCXNcmI6O7TDINutbaicEUpoYFR1rWqn3kTbulfMhT0iaPFurLz2ddEcWe3BiciaQ/0, createdBy=5f6e1724878, createdName=136****0753赵, createdTime=Sat Nov 19 11:55:18 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156784, encodeId=8fe3156e842d, content=这个研究背后问题很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 19 08:53:34 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156746, encodeId=4a48156e46e3, content=学习一下，赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sat Nov 19 07:18:28 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156706, encodeId=d78c156e06c4, content=学习了，多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Nov 19 00:04:25 CST 2016, time=2016-11-19, status=1, ipAttribution=)]
    2016-11-19 lovetcm

    这个研究背后问题很多

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1642327, encodeId=10e5164232ebc, content=<a href='/topic/show?id=2e74e3891da' target=_blank style='color:#2F92EE;'>#磺酰脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73891, encryptionId=2e74e3891da, topicName=磺酰脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592c22907703, createdName=12498dabm84暂无昵称, createdTime=Sun Jan 15 10:49:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901506, encodeId=4ec4190150692, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 16 14:49:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759821, encodeId=6a361e59821ff, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Jul 27 09:49:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637551, encodeId=896e163e55120, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 19 12:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319264, encodeId=b3371319264c6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415991, encodeId=c62b141599136, content=<a href='/topic/show?id=f60890462d4' target=_blank style='color:#2F92EE;'>#西他列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90462, encryptionId=f60890462d4, topicName=西他列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f33125782, createdName=tcm100hq, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156862, encodeId=f08f156862af, content=值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMzGpMQ8w4I7FpiblCXNcmI6O7TDINutbaicEUpoYFR1rWqn3kTbulfMhT0iaPFurLz2ddEcWe3BiciaQ/0, createdBy=5f6e1724878, createdName=136****0753赵, createdTime=Sat Nov 19 11:55:18 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156784, encodeId=8fe3156e842d, content=这个研究背后问题很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 19 08:53:34 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156746, encodeId=4a48156e46e3, content=学习一下，赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sat Nov 19 07:18:28 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156706, encodeId=d78c156e06c4, content=学习了，多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Nov 19 00:04:25 CST 2016, time=2016-11-19, status=1, ipAttribution=)]
    2016-11-19 老段

    学习一下，赞了！

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1642327, encodeId=10e5164232ebc, content=<a href='/topic/show?id=2e74e3891da' target=_blank style='color:#2F92EE;'>#磺酰脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73891, encryptionId=2e74e3891da, topicName=磺酰脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592c22907703, createdName=12498dabm84暂无昵称, createdTime=Sun Jan 15 10:49:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901506, encodeId=4ec4190150692, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Jan 16 14:49:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759821, encodeId=6a361e59821ff, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Jul 27 09:49:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637551, encodeId=896e163e55120, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 19 12:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319264, encodeId=b3371319264c6, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415991, encodeId=c62b141599136, content=<a href='/topic/show?id=f60890462d4' target=_blank style='color:#2F92EE;'>#西他列汀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90462, encryptionId=f60890462d4, topicName=西他列汀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37f33125782, createdName=tcm100hq, createdTime=Sun Nov 20 07:49:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156862, encodeId=f08f156862af, content=值得学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMzGpMQ8w4I7FpiblCXNcmI6O7TDINutbaicEUpoYFR1rWqn3kTbulfMhT0iaPFurLz2ddEcWe3BiciaQ/0, createdBy=5f6e1724878, createdName=136****0753赵, createdTime=Sat Nov 19 11:55:18 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156784, encodeId=8fe3156e842d, content=这个研究背后问题很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 19 08:53:34 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156746, encodeId=4a48156e46e3, content=学习一下，赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sat Nov 19 07:18:28 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156706, encodeId=d78c156e06c4, content=学习了，多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Sat Nov 19 00:04:25 CST 2016, time=2016-11-19, status=1, ipAttribution=)]
    2016-11-19 1e1263e3m20(暂无匿称)

    学习了，多谢分享

    0

以上为热门评论，梅斯医学App还有更多内容